HC Wainwright Brokers Raise Earnings Estimates for AMLX

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings estimates for Amylyx Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.34) per share for the quarter, up from their previous forecast of ($0.40). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.34) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at ($1.25) EPS, FY2028 earnings at ($0.93) EPS, FY2029 earnings at $1.83 EPS and FY2030 earnings at $3.93 EPS.

AMLX has been the subject of several other research reports. Bank of America raised their price objective on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Finally, Stifel Nicolaus initiated coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $21.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.56.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX stock opened at $14.10 on Friday. The business’s fifty day moving average is $13.91 and its 200-day moving average is $13.17. The stock has a market cap of $1.56 billion, a PE ratio of -9.10 and a beta of -0.31. Amylyx Pharmaceuticals has a 1 year low of $3.11 and a 1 year high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director Karen Firestone bought 8,100 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average cost of $12.45 per share, for a total transaction of $100,845.00. Following the completion of the purchase, the director directly owned 63,100 shares of the company’s stock, valued at $785,595. The trade was a 14.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Justin B. Klee sold 1,995 shares of Amylyx Pharmaceuticals stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the sale, the chief executive officer directly owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. The trade was a 0.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,203 shares of company stock valued at $2,028,385 in the last three months. 12.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. boosted its holdings in Amylyx Pharmaceuticals by 17.5% during the fourth quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after acquiring an additional 1,825 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Amylyx Pharmaceuticals by 54.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after acquiring an additional 1,890 shares during the period. Meeder Asset Management Inc. bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $25,000. China Universal Asset Management Co. Ltd. raised its stake in Amylyx Pharmaceuticals by 14.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,895 shares of the company’s stock valued at $216,000 after purchasing an additional 2,265 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Amylyx Pharmaceuticals by 13.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company’s stock valued at $326,000 after purchasing an additional 3,198 shares during the period. Institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.